Cancer pharmacogenomics: Achievements in basic research

International Journal of Clinical Oncology

Volumn 10, Issue 1, 2005, Pages 14-19

  Nakajima, Miki ^a   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Cytochrome P450; Drug metabolizing enzymes; Genetic polymorphism; Interindividual variability

Indexed keywords

3,5 DIMETHYL 2 (3 PYRIDYL) 4 THIAZOLIDINONE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 2A6; DOCETAXEL; DOXORUBICIN; DRUG METABOLIZING ENZYME; ETOPOSIDE; FLUOROURACIL; HALOTHANE; IFOSFAMIDE; PACLITAXEL; TAMOXIFEN; TEGAFUR; TENIPOSIDE; VALPROIC ACID; VINBLASTINE; VINCRISTINE; VINDESINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESEARCH; DRUG CLEARANCE; DRUG METABOLISM; GENE DUPLICATION; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; INHERITANCE; OVARY CANCER; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 15044351719     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-004-0463-8     Document Type: Review

References (94)

1. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83-448
2. Fernandez-Salguero P, Gonzalez FJ (1995) The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics 5:8123-128
3. Yamano S, Tatsuno J, Gonzalez FJ (1990) The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29:1322-1329
4. Ding S, Lake BG, Friedberg T, et al. (1995) Expression and alternative splicing of the cytochrome P450 CYP2A7. Biochem J 306:161-166
5. Nakajima M, Yamamoto T, Nunoya K, et al. (1996) Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24:1212-1217
6. Nakajima M, Kuroiwa Y, Yokoi T (2002) Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6. Drug Metab Rev 34:865-877
7. Komatsu T, Yamazaki H, Shimada N, et al. (2000) Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos 28:1457-1463
8. Ikeda K, Yoshisue K, Matsushima E, et al. (2000) Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res 6:4409-4415
9. Nunoya K-I, Yokoi T, Kimura K, et al. (1999) A new CYP2A gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3- pyridyl) thiazolidin-4-one hydrochloride in humans. J Pharmacol Exp Ther 289:437-442
10. Nakajima M, Kwon J-T, Tanaka N, et al. (2001) Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 68:72-78
11. Oscarson M, McLellan RA, Gullsten H, et al. (1999) Identification and characterization of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett 460:321-327
12. Kitagawa K, Kunugita N, Kitagawa M, et al. (2001) CYP2A6*6, a novel polymorphism in cytochrome P450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J Biol Chem 276:17830-17835
13. Ariyoshi N, Sawamura Y, Kamataki T (2001) A novel single nucleotide polymorphism altering stability and activity of CYP2A. Biochem Biophys Res Commun 281:810-814
14. Yoshida R, Nakajima M, Watanabe Y, et al. (2002) Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br J Clin Pharmacol 54:511-517
15. Daigo S, Takahashi Y, Fujieda M, et al. (2002) A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 12:299-306
16. Fukami T, Nakajima M, Yoshida R, et al. (2004) A novel polymorphism of human CYP2A6 gene, CYP2A6*17, has an amino acid substitution (V365M) that reduces enzymatic activity. Clin Pharmacol Ther 76:519-527
17. Pitarque M, von Richter O, Oke B, et al. (2001) Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun 284:455-460
18. Yoshida R, Nakajima M, Nishimura K, et al. (2003) Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 74:69-76
19. Oscarson M, McLellan RA, Asp V, et al. (2002) Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum Mutat 20:275-283
20. Rao Y, Hoffmann E, Zia M, et al. (2000) Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 58:747-755
21. Nakajima M, Yamagishi S, Yamamoto H, et al. (2000) Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clin Pharmacol Ther 67:57-69
22. Kwon JT, Nakajima M, Chai S, et al. (2001) Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics 11:317-323
23. Yoshida R, Nakajima M, Watanabe Y, et al. (2002) Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br J Clin Pharmacol 54:511-517
24. Komatsu T, Yamazaki H, Shimada N, et al. (2001) Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver. Clin Cancer Res 7:675-681
25. Ozawa S, Hamada M, Murayama N, et al. (2002) Cytosolic and microsomal activation of doxifluridine and tegafur to produce 5-fluorouracil in human liver. Cancer Chemother Pharmacol 50:454-458
26. Chang TK, Weber GF, Crespi CL, et al. (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53:5629-5637
27. Roy P, Yu LJ, Crespi CL, et al. (1999) Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 27:655-666
28. Huang Z, Roy P, Waxman DJ. (2000) Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 59:961-972
29. Sladek NE (1988) Metabolism of oxazaphosphorines. Pharmacol Ther 37:301-355
30. Lang T, Klein K, Fischer J, et al. (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415
31. Ariyoshi N, Miyazaki M, Toide K, et al. (2001) A single nucleotide polymorphism of CYP2B6 found in Japanese enhances catalytic activity by autoactivation. Biochem Biophys Res Commun 281:1256-1260
32. Jinno H, Tanaka-Kagawa T, Ohno A, et al. (2003) Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 31:398-403
33. Lamba V, Lamba J, Yasuda K, et al. (2003) Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307:906-922
34. Lang T, Klein K, Richter T, et al. (2004) Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther 311:34-43
35. Hesse LM, He P, Krishnaswamy S, et al. (2004) Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14:225-238
36. Xie HJ, Yasar U, Lundgren S, et al. (2003) Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 3:53-61
37. Hiratsuka M, Takekuma Y, Endo N, et al. (2002) Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 58:417-421
38. Horwitz SB, Lothstein L, Manfredi JJ, et al. (1986) Taxol: mechanisms of action and resistance. Ann N Y Acad Sci 466:433-444
39. Rahman A, Korzekwa KR, Grogan J, et al. (1994) Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546
40. Harris JW, Katki A, Anderson LW, et al. (1994) Isolation, structural determination, and biological activity of 6α-hydroxytaxol, the principal human metabolite of taxol. J Med Chem 37:706-709
41. Dai D, Zeldin DC, Blaisdell JA, et al. (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597-607
42. Bahadur N, Leathart JB, Mutch E, et al. (2002) CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochem Pharmacol 64:1579-1589
43. Soyama A, Saito Y, Komamura K, et al. (2002) Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metab Pharmacokinet 17:374-377
44. Soyama A, Saito Y, Hanioka N, et al. (2001) Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol Pharm Bull 24:1427-1430
45. Nakajima M, Fujiki Y, Kyo S, et al. (2003) Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab Dispos 31:687-690
46. Zanger UM, Fischer J, Raimundo S, et al. (2001) Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11:573-585
47. Zanger UM, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369:23-37
48. Daly AK, Brockmoller J, Broly F, et al. (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6:193-201
49. Cascorbi I (2003) Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication. Eur J Clin Invest 33(Suppl 2):17-22
50. Sachse C, Brockmoller J, Bauer S, et al. (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295
51. Kirchheiner J, Heesch C, Bauer S, et al. (2004) Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 76:302-312
52. Kitada M (2003) Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6. Int J Clin Pharmacol Res 23:31-35
53. Mihara K, Suzuki A, Kondo T, et al. (1999) Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin Pharmacol Ther 65:291-294
54. Dehal SS, Kupfer D (1997) CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 57:3402-3406
55. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618
56. Clarke R, Leonessa F, Welch JN, et al. (2001) Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53:25-71
57. Stearns V, Johnson MD, Rae JM, et al. (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764
58. Desta Z, Ward BA, Soukhova NV, et al. (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062-1075
59. Shimada T, Yamazaki H, Mimura M, et al. (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423
60. Gellner K, Eiselt R, Hustert E, et al. (2001) Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 11:111-121
61. Krusekopf S, Roots I, Kleeberg U. (2003) Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. Eur J Pharmacol 466:7-12
62. Domanski TL, Finta C, Halpert JR, et al. (2001) cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 59:386-392
63. Kuehl P, Zhang J, Lin Y, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391
64. Koch I, Weil R, Wolbold R, et al. (2002) Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30:1108-1114
65. Westlind A, Malmebo S, Johansson I, et al. (2001) Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 281:1349-1355
66. Rendic S, Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413-580
67. Daly AK, Cholerton S, Gregory W, et al. (1993) Metabolic polymorphisms. Pharmacol Ther 57:129-160
68. Watkins PB (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171-184
69. Sata F, Sapone A, Elizondo G, et al. (2000) CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 67:48-56
70. Hsieh KP, Lin YY, Cheng CL, et al. (2001) Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 29:268-273
71. Eiselt R, Domanski TL, Zibat A, et al. (2001) Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11:447-458
72. Garcia-Martin E, Martinez C, Pizarro RM, et al. (2002) CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 71:196-204
73. Dai D, Tang J, Rose R, et al. (2001) Identification of variants of CYP3A4 and characterization of their abilities to metabolize test-osterone and chlorpyrifos. J Pharmacol Exp Ther 299:825-831
74. Fukushima-Uesaka H, Saito Y, Watanabe H, et al. (2004) Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 23:100
75. Rebbeck TR, Jaffe JM, Walker AH, et al. (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90:1225-1229
76. Westlind A, Lofberg L, Tindberg N, et al. (1999) Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 259:201-205
77. Hamzeiy H, Vahdati-Mashhadian N, Edwards HJ, et al. (2002) Mutation analysis of the human CYP3A4 gene 5′ regulatory region: population screening using non-radioactive SSCP. Mutat Res 500:103-110
78. Saeki M, Saito Y, Nakamura T, et al. (2003) Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum Mutat 21:653
79. Chou FC, Tzeng SJ, Huang JD (2001) Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab Dispos 29:1205-1209
80. Hustert E, Haberl M, Burk O, et al. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779
81. Lee SJ, Usmani KA, Chanas B, et al. (2003) Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 13:461-472
82. Relling MV, Evans R, Dass C, et al. (1992) Human cytochrome P450 metabolism of teniposide and etoposide. J Pharmacol Exp Ther 261:491-496
83. Wacher VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134
84. Zhou-Pan XR, Seree E, Zhou XJ, et al. (1993) Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 53:5121-5126
85. Zhou XJ, Zhou-Pan XR, Gauthier T, et al. (1993) Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochem Pharmacol 45:853-861
86. Kivisto KT, Kroemer HK, Eichelbaum M (1995) The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40:523-530
87. Walker D, Flinois JP, Monkman SC, et al. (1994) Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 47:1157-1163
88. Royer I, Monsarrat B, Sonnier M, et al. (1996) Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 56:58-65
89. Hirth J, Watkins PB, Strawderman M, et al. (2000) The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 6:1255-1258
90. Goh BC, Lee SC Wang LZ, et al. (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20:3683-3690
91. Kishi S, Yang W, Boureau B, et al. (2004) Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 103:67-72
92. Chabot GG (1994) Factors involved in clinical pharmacology variability in oncology. Anticancer Res 14:2269-2272
93. Marsh S, McLeod HL (2004) Cancer pharmacogenetics. Br J Cancer 90:8-11
94. Desai AA, Innocenti F, Ratain MJ (2003) UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics 13:517-523